Showing 23,074 news articles about PEP

Filters Content type: Editors' picks Topic: PEP

Post-exposure prophylaxis involves taking a 28-day course of anti-HIV drugs, after possible exposure to HIV. It may be used by healthcare workers (occupational PEP) or after sex (post-exposure prophylaxis after sexual exposure, PEPSE, also known as non-occupational PEP or nPEP).

New & experimental hepatitis C treatment

Promising data bodes well for all-Achillion hep C treatment

Editor's pick
Reuters
10 February 2015
Hepatitis C treatment

What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean

Editor's pick
Wall Street Journal (blog)
5 February 2015
Hepatitis B

Hepatitis Quest Moves From C to B Under Former Gilead Executives

Editor's pick
Bloomberg
5 February 2015
New & experimental hepatitis C treatment

Merck says hepatitis C drugs to lose breakthrough status

Editor's pick
Reuters
5 February 2015
Hepatitis C transmission & prevention

Hepatitis C more prevalent than HIV/AIDS or Ebola yet lacks equal attention

Editor's pick
Medical Xpress
5 February 2015
Finance & funding

How Hepatitis C Is Shining A Light On Critical Gaps In Payment Reform

Editor's pick
Health Affairs (blog)
4 February 2015
Hepatitis C treatment

Gilead and AbbVie take hepatitis C battle to Europe

Editor's pick
Financial Times (free registration required)
20 January 2015
Access to healthcare

Hepatitis C drug delayed by NHS due to high cost

Editor's pick
The Guardian
16 January 2015
Hepatitis C treatment

How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

Editor's pick
The Motley Fool
15 January 2015
Hepatitis C symptoms & diagnosis

Doctors Question Wider Hepatitis C Screening Despite Cures

Editor's pick
Bloomberg
14 January 2015
Access to healthcare

Spaniards rally over hepatitis C drugs

Editor's pick
Press TV
12 January 2015
Hepatitis C treatment

VA, DoD spend more than $450M on costly hepatitis drug

Editor's pick
USA Today
9 January 2015
Hepatitis C treatment

Anthem selects Gilead as primary supplier of hepatitis C drugs

Editor's pick
Reuters
9 January 2015
Hepatitis C treatment

Gilead Strikes Hepatitis Drug Deal With CVS Health

Editor's pick
New York Times
7 January 2015
Hepatitis C treatment

Third of 2015 health basket expansion in Israel goes to hepatitis C

Editor's pick
Jerusalem Post
4 January 2015
Hepatitis C treatment

Gilead slides after hepatitis drug setback

Editor's pick
Financial Times (free registration required)
23 December 2014
New & experimental hepatitis C treatment

US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

Editor's pick
Reuters
20 December 2014
Hepatitis C treatment

Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug

Editor's pick
Insurance News Net
17 December 2014
Hepatitis C symptoms & diagnosis

Scaling up screening for viral hepatitis in Europe

Editor's pick
Medical Xpress
15 December 2014
Hepatitis C treatment

Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug

Editor's pick
Nasdaq
11 December 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead

Editor's pick
Bloomberg
10 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Hepatitis C treatment

Australia's rejection of costly new treatment sofosbuvir a 'death sentence for for Hepatitis C sufferers'

Editor's pick
ABC Online
27 October 2014